Related Experiment Video
Updated: Aug 6, 2026

Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
[Therapy for spontaneous intracerebral haemorrhage]
E Sammler1, E Juettler, K Geletneky
1Neurologische Klinik, Universität Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg. Esther.Sammler@med.uni-heidelberg.de
Insights
Spontaneous intracerebral haemorrhage (ICH) is a severe stroke type with high mortality. New research and upcoming European guidelines offer improved understanding and treatment options for this critical neurological condition.
Area of Science:
- Neurology
- Vascular Medicine
- Critical Care Medicine
Context:
- Spontaneous intracerebral haemorrhage (ICH) constitutes a significant portion of all strokes, carrying a mortality rate exceeding 50%.
- Key risk factors for ICH include advanced age and hypertension, alongside vascular malformations, coagulation disorders, and anticoagulant/thrombolytic use.
- Understanding ICH etiology and management is crucial for improving patient outcomes.
Purpose:
- To provide an overview of spontaneous intracerebral haemorrhage (ICH).
- To discuss current and emerging treatment strategies for ICH.
- To highlight upcoming European recommendations for ICH management.
Summary:
- ICH is a major cause of stroke with high mortality, influenced by factors like age and hypertension.
- Treatment encompasses conservative and surgical approaches, with novel haemostatic therapies like activated recombinant Factor VII showing promise.
- The article is based on forthcoming recommendations from the European Stroke Initiative.
Impact:
- Enhances understanding of ICH pathophysiology and risk factors.
- Informs clinical practice regarding conservative, surgical, and pharmacological interventions for ICH.
- Facilitates the implementation of evidence-based management strategies following new European guidelines.
Abstract:
Spontaneous intracerebral haemorrhage (ICH) is a common and serious disease. It is responsible for 10-17% of all strokes, and mortality exceeds 50%. A variety of underlying causes exist for ICH, advancing age and hypertension being the most important risk factors. Other causes of ICH include vascular malformations, coagulation disorders, and use of anticoagulants and thrombolytic agents. Treatment options comprise conservative as well as surgical management. In addition, a recently published clinical trial evaluating the use of activated recombinant Factor VII allows specific haemostatic therapies to be used in ICH treatment. That and other studies have significantly added to the understanding of the disease. The European Stroke Initiative, which represents the European Stroke Council, European Neurological Society, and European Federation of Neurological Societies, will soon publish recommendations for the management of spontaneous intracerebral haemorrhages. Those recommendations form the basis of this article.
Related Concept Videos
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Ischemic Stroke ll: Pathophysiology
Cerebral Edema ll: Pathophysiology
Increased Intracranial Pressure l: Introduction
